rEVO Biologics
9
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
33.3%
3 terminated/withdrawn out of 9 trials
66.7%
-19.8% vs industry average
56%
5 trials in Phase 3/4
83%
5 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients
Role: collaborator
Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia
Role: lead
Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors
Role: lead
Understanding "Heparin Resistance" in Cardiac Surgery
Role: collaborator
Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery
Role: collaborator
Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates
Role: collaborator
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
Role: lead
Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.
Role: lead
Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery
Role: lead
All 9 trials loaded